Session Information
Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Nearly 90% of patients with scleroderma (SSc) have gastrointestinal tract(GIT) involvement in variable severities and is a challenging process for clinicians.The University of California Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0(UCLA SCTC GIT 2.0) is a questionnaire including 34 items, 7 multi-item scales :reflux, distention/bloating, diarrhea, fecal soilage, constipation, emotional well-being and social functioning. By these parameters, a total GIT score is calculated (1). This scale translated in German, Italian, French, Polish, Spanish, Swedish, Dutch before, they are available in http://www.uclascleroderma.researchcore.org/ website (1,2,3). There is no Turkish version of this scale yet. Our aim is to make translation, cultural adaptation of UCLA SCTC GIT 2.0 into Turkish, and assess reliability of the scale in patients speaking Turkish.
Methods: UCLA SCTC GIT 2.0 scale was translated into Turkish according to international guidelines and applied to 97 SSc patients. The questionnaire repeated in 29 patients after an interval of 15 days for determining reliability. For internal consistency, Cronbach’s alpha was calculated, reliability coefficient if item deleted and test-retest reliability also determined. External consistency was measured by comparing with the Short Form(SF)-36 by Spearman’s correlation analysis (rho: ≤ 0.29 weak, 0.30-0.49 middle, ≥ 0.50 strong).
Results: 97 scleroderma patients were included in this study (female:87.6%, mean age:55.4±11.4). Internal consistency Cronbach’s alpha was calculated as 0.89, reliability coefficient if item deleted was 0.89-0.90. External consistency of UCLA SCTC GIT 2.0 was measured by comparing with the SF-36, correlation was meaningful in medium level (Table 1,2).
Conclusion: UCLA SCTC GIT 2.0 scale had strong internal consistency, good reliability and acceptable validity when adapted into Turkish. Turkish-speaking patients with scleroderma, this scale will useful to assess GIT symptoms. The basic constraint of our study was, not using image procedures for objective GIT involvement evidences.
| Table 1. Descriptive Statistics and Internal Consistency Statistics. | |||||||
| UCLA SCTC GIT 2.0 Scale |
n |
Mean score (SD) |
Minimum score |
Maximum score |
Cronbach alpha |
Floor Effect % |
Ceiling Effect % |
| Reflux |
97 |
0.64 (0.54) |
0.0 |
2.6 |
0.83 |
17.5 |
0.0 |
| Distension |
97 |
1.02 (0.75) |
0.0 |
3.0 |
0.58 |
7.2 |
1.0 |
| Soilage |
97 |
0.30 (0.72) |
0.0 |
3.0 |
0.68 |
82.5 |
3.1 |
| Diarrhea |
97 |
0.28 (0.47) |
0.0 |
1.5 |
0.36 |
69.1 |
0.0 |
| Social Functioning |
97 |
0.17 (0.32) |
0.0 |
1.3 |
0.47 |
67.0 |
0.0 |
| Emotional Wellbeing |
97 |
0.30 (0.43) |
0.0 |
2.2 |
0.73 |
41.2 |
0.0 |
| Constipation |
97 |
0.63 (0.69) |
0.0 |
2.5 |
0.56 |
34.0 |
0.0 |
| Total GIT score |
97 |
0.45 (0.37) |
0.0 |
1.6 |
0.82 |
3.1 |
0.0 |
| All scales are scored from 0.00(better HRQOL) to 3.00(worse HRQOL) except the diarrhea and constipation (range from 0.00–2.00 and 0.00–2.50, respectively). The UCLA GIT 2.0 provides a total score of GIT severity and calculated by summation of all scales (except constipation) and ranges from 0.00–2.83(2). | |||||||
. .
| Table 2. External Consistency Statistics: Correlation Between SF-36 Items and Component Summaries and UCLA SCTC GIT 2.0 Items | ||||||||||
| UCLA SCTC GIT 2.0 / SF-36 | RF | RP | RE | VT | MH | SF | BP | GH | PCS | MCS |
| Reflux | -,300 ** | -,436 ** | -,296** | -,421** | -,373** | -,235* | -,427** | -,312** | -,386** | -,313** |
| Distension | -,461 ** | -,422 ** | ,258* | -,465** | -,474** | -,340** | -,427** | -,408** | -,437** | -,354** |
| Soilage | -,237 * | -,160 | ,001 | -,170 | -,165 | -,131 | -,328** | -,114 | -,254* | -,027 |
| Diarrhea | -,265 ** | -,258 * | -,180 | -,216* | -,215* | -,146 | -,325** | -,083 | -,296** | -,174 |
| Social Functioning | -,208 * | -,203 * | -,242* | -,149 | -,271** | -,210* | -,400** | -,242* | -,300** | -,243* |
| Emotional Wellbeing | -,397 ** | -,379 ** | -,433** | -,334** | -,372** | -,337** | -,445** | -,263** | -,304** | -,368** |
| Constipation | -,163 | -,101 | -,199 | -,047 | -,063 | -,166 | -,299** | -,065 | -,167 | -,132 |
| Total GIT score | -,482 ** | -,453 ** | -,321** | -,492** | -,493** | -,369** | -,560** | -,395** | -,482** | -,343** |
| p<0.05 * and p<0.01 **. RF: physical functioning, RP: role limitations due to physical health, RE: role limitations due to emotional problems, VT: vitality, MH: mental health, SF: social functioning, BP: bodily pain, GH: general health, PCS: physical component summary, MCS: mental component summary. | ||||||||||
References:
1)Khanna D, Reliability and validity of the UCLA SCTC GIT Instrument.Arthritis Rheum,2009.
2) Bae S, Development and validation of French version of the UCLA SCTC GIT Instrument.Clin Exp Rheumatol, 2011.
3) Meijs J, Translation,cross-cultural adaptation, and validation of the UCLA SCTC GIT 2.0 into Dutch. Clin Exp Rheumatol,2014.
Disclosure: M. Y. Tas, None; G. Dervis Hakim, None; P. Keskinoglu, None; G. Kenar, None; H. Yarkan, None; B. Zengin, None; G. Can, None; F. Onen, None; N. Akkoc, None; M. Akarsu, None; M. Birlik, None.To cite this abstract in AMA style:
Tas MY, Dervis Hakim G, Keskinoglu P, Kenar G, Yarkan H, Zengin B, Can G, Onen F, Akkoc N, Akarsu M, Birlik M. Adaptation of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Questionnaire into Turkish [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/adaptation-of-ucla-scleroderma-clinical-trial-consortium-gastrointestinal-tract-2-0-questionnaire-into-turkish/. Accessed .« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/adaptation-of-ucla-scleroderma-clinical-trial-consortium-gastrointestinal-tract-2-0-questionnaire-into-turkish/